Pharmaceutical Industry News Archive
Get news By email or subscribe to our News feeds.
October 2009
October 1
FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies
Fovea Pharmaceuticals to be Acquired by sanofi-aventis
Pfizer Receives Approval From Australian Competition And Consumer Commission (ACCC) For Pending Acquisition Of Wyeth
Repros Therapeutics Inc. Provides Update on Proellex
Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
Sanofi-Aventis to Buy Abingworth Portfolio Company Fovea
MarkMonitor Finds Online Drug Brand Abuse is Growing
FDA Warning Letters Caused Dramatic Decline in Sponsored Link Exposures, According to comScore
FDA Alert: New USP Standards for Heparin Products Will Result in Decreased Potency
October 2
Allergan Files Federal Lawsuit to Allow It to Share Relevant Information with the Medical Community on the Safe Use of Botox for Common Therapeutic Off-Label Treatments
Avexa Closes ATC's Phase III Trial to Evaluate Data
Baxter Receives EMEA Positive Opinion for CELVAPAN H1N1 Pandemic Influenza Vaccine
Jeffrey B. Kindler and James S. Tisch to Join New York Fed Board of Directors
Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro (escitalopram oxalate) ANDA Patent Litigation
October 5
Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial
Pharmaceutical Companies Rebrand Speaker Programs to Meet Changing Political and Regulatory Landscape, Says New Study by Cutting Edge Information
SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
Daiichi Sankyo to Leverage Ranbaxy's Presence in Mexico for Marketing and Distribution
Physician Smartphone Adoption Rate to Reach 81% in 2012
License to Market Kremezin (drug for chronic renal failure) in Japan
CombinatoRx-Derived Combination Drug Candidate, Prednisporin, Acquired by Sanofi-Aventis Through Proposed Acquisition of Fovea Pharmaceuticals
Phase 2 Trial Of Rp101 In Late-Stage Pancreatic Cancer Discontinued
In the battle against cancer, ?future progress depends on personalisation of healthcare? says AstraZeneca Chief Executive
October 6
October 7
October 8
Novartis Gains Exclusive Worldwide Rights to PTK 0796, in Phase III Study as Potential First-in-Class IV and Oral Broad-Spectrum Antibiotic
IMS Health Forecasts Global Pharmaceutical Market Growth of 4 - 6 Percent in 2010; Predicts 4 - 7 Percent Expansion Through 2013
Cancer Drugs Emerging as Top Driver of Specialty Drug Spending
October 9
GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for FUSILEV in Advanced Metastatic Colorectal Cancer
Vaccinating Boys Against Human Papillomavirus Not Cost-Effective
ReachMD XM 160 Announces Two New Radio Programming Series - Featuring the New England Journal of Medicine
October 13
Johnson & Johnson Reports 2009 Third-Quarter Results:
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt, an FDA-Approved Oral Therapy for Schizophrenia
Prosensa and GlaxoSmithKline Form Alliance to Fight Duchenne Muscular Dystrophy
Medafor Selects AllOut Marketing as Medical Marketing Partner
Shire and Sandoz Settle all Pending Litigation Concerning Adderall XR
PhRMA Statement on Senate Finance Committee Vote
October 14
FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets
Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. Announce Successful Tender Offer and Commencement of Subsequent Offering Period
Acorda Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Review Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
Elan Corporation PLC Announces Results to Date of Tender Offer for 7¾% Senior Fixed Rate Notes Due 2011
Pfizer Announces Settlement And License Agreement With Mylan Related To Vfend
Abbott Reports 16.5 Percent Earnings Growth in Third Quarter; Raises Earnings Guidance for 2009
Galapagos Expands Strategic Alliance in Metabolic Disease with Merck & Co., Inc.
CSL Donates 3 Million Doses of Pandemic H1N1 2009 Vaccine to the World Health Organisation (WHO) for Use in Low-Income Countries in this Region
Sample Accountability Shows Stepped-Up Focus
October 15
New FDA Web Page Lists Disposal Instructions for Select Medicines
Baxter Reports Double-Digit EPS Growth for Third Quarter 2009
La Jolla Pharmaceutical Company to Seek Stockholder Approval of Dissolution
Roche reports further accelerated sales growth in third quarter
Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax Sprinkle Capsules
Interpublic Aligns Deutsch Inc. and Lowe Worldwide
Loomis Group Health, Capella Advisors Form Strategic Partnership to Guide Healthcare Companies from Clinical Trials to Marketplace
comScore Study Finds the Internet a Key Component in Consumer Research on Prescriptions and Health Conditions
Pfizer Completes Acquisition Of Wyeth
October 16
October 21
October 22
IMS Health Announces 2009 Third-Quarter Results
Merck Announces Third-Quarter 2009 Financial Results
Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter
Centron Wins Agency Of Record Assignments From Strativa
Schering-Plough Reports Financial Results for 2009 Third Quarter
Novartis delivers strong new product momentum and operational performance in first nine months of 2009
Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49
GE and Lilly Achieve Significant Advancement in Cancer Research
Angela Cole Joins Lyonheart As Executive Vice President, Director Of Client Services
October 23
October 26
Q3/2009: Merck KGaA Revenues Increase by 2.7% to ? 1.9 Billion
S&R Communications Group Reengineers Into S+R Medical Communications And Friday Morning
Blue Spoon Consulting Publishes Strategy Innovation for Established Drug Brands
Grassley Says Drug Companies Should Disclose Payments, Seeks Greater Transparency
October 27
Bayer back on the uptrend
Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
Changing Behavior Helps Patients Take Medication as Prescribed
Vertiyo Creative Services Launches Pharma Division
Vertiyo Creative Group Announces Vertiyo Health, New Unit Focused on Pharmaceutical Marketing
October 28
Neurobiological Technologies Announces Stockholder Approval of Plan of Liquidation and Dissolution
FDA Sends Letter to Sanofi-Aventis Regarding Uroxatral Promotion
GSK delivers Q3 EPS of 28.5p before major restructuring and dividend of 15p up 7%
Use of Antipsychotic Medications by Children and Adolescents Associated With Significant Weight Gain
HealthCentral partners with online video startup to create largest health video network
October 29
Alcon Posts 5.9 Percent Sales Growth for Third Quarter
P&G First Quarter Sales and EPS Exceed Expectations
AstraZeneca: Third Quarter and Nine Months Results 2009
Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32
Allergan Reports Third Quarter 2009 Operating Results
AstraZeneca PLC Third Quarter & Nine Months Results 2009
Novo Nordisk Interim Financial Report for nine months ending 30 September 2009
October 30
Pfizer's Board Of Directors Approves Shareholder Advisory Vote On Executive Compensation
Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Geron and FDA Reach Agreement on Clinical Hold
States file kickback lawsuit against biotech giant Amgen
